Jpmorgan Chase & CO Olema Pharmaceuticals, Inc. Transaction History
Jpmorgan Chase & CO
- $1.14 Trillion
- Q2 2024
A detailed history of Jpmorgan Chase & CO transactions in Olema Pharmaceuticals, Inc. stock. As of the latest transaction made, Jpmorgan Chase & CO holds 23,861 shares of OLMA stock, worth $282,991. This represents 0.0% of its overall portfolio holdings.
Number of Shares
23,861
Previous 22,885
4.26%
Holding current value
$282,991
Previous $259,000
0.39%
% of portfolio
0.0%
Previous 0.0%
Shares
11 transactions
Others Institutions Holding OLMA
# of Institutions
129Shares Held
57.8MCall Options Held
57.5KPut Options Held
34K-
Bvf Inc San Francisco, CA9.14MShares$108 Million3.02% of portfolio
-
Paradigm Biocapital Advisors LP New York, NY7.9MShares$93.7 Million3.46% of portfolio
-
Deep Track Capital, LP Greenwich, CT4MShares$47.4 Million1.42% of portfolio
-
Black Rock Inc. New York, NY4MShares$47.4 Million0.0% of portfolio
-
Steven Cohen Point72 Asset Management, L.P. | Stamford, Ct3.21MShares$38.1 Million0.1% of portfolio
About Olema Pharmaceuticals, Inc.
- Ticker OLMA
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 40,419,600
- Market Cap $479M
- Description
- Olema Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapies for women's cancers. Its lead product candidate is OP-1250, an estrogen receptor (ER) antagonist and a selective ER degrader, which is in Phase 1/2 clinical trial for the treatment of recurrent, local...